866-997-4948(US-Canada Toll Free)

Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Oct 2010

Category :

Cancer

No. of Pages : 89 Pages

 

GlobalData, the industry analysis specialists new report, Cancer Vaccines Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global Cancer vaccines market. The report identifies key trends shaping and driving the global Atopic dermatitis disease market. It also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cancer vaccines sector.

 

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in house analysis by GlobalDatas team of industry experts. 

 

GlobalData has estimated that the global cancer vaccines market in 2009 was worth $1.8 billion. There are currently two products, which constitute the global cancer vaccines market. These are Gardasil and Cervarix used for the treatment of cervical cancer. Oncophage has also been approved for kidney cancer but only in Russia. Hence the market forecasts do not include this vaccine. The present pipeline for cancer vaccines seems to be very promising with numerous molecules present in the Phase II and III stages. From the market perspective, there are going to be multiple launches of vaccines between 2010 and 2013-14, which would substantially increase the market size and growth. The cost of three complete dose courses of the vaccines ranges approximately from $380 to $400.

 

The cancer vaccines developmental pipeline is strong with about 239 products in various phases of clinical development including 21 molecules in Phase III. The Phase III pipeline activity is strong. It mainly consists of clinical studies involving antigen/adjuvant vaccines regimen. The Phase III pipeline contains some novel therapeutic vaccines. These options are also present in the Phase II stage pipeline. With all these factors, it is likely that the options in the pipeline will cause a dramatic change to the market in the near future and the market activity will primarily be dominated by the molecules in the Phase II and Phase I pipeline

 

Scope

 

The scope of the report includes -

 

  • Annualized global cancer vaccines market revenues data from 2001 to 2009, forecast forward for eight years to 2017
  • Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
  • Analysis of the current and future market competition in the global cancer vaccines market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with cancer vaccines.

 

Reasons to buy

 

The report will enhance your decision making capability. It will allow you to -

 

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global cancer vaccines market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global cancer vaccines market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify the emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Whats the next big thing in the global cancer vaccines market landscape? Identify, understand and capitalize.

Table Of Content

 

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

 

2 Cancer Vaccines: Introduction 6
2.1 GlobalData Pipeline Report Guidance 7
 

3 Cancer Vaccines: Market Characterization 8
3.1 Overview 8
3.2 Cervical Cancer Vaccines 8
3.3 Cervical Cancer Vaccines Market Size 8
3.4 Cervical Cancer Vaccines Market Forecast and CAGR 9
3.5 Drivers and Barriers for the Global Cervical Cancer Vaccines Market 10
3.5.1 Drivers for the Global Cancer Vaccines Market 10
3.5.2 Barriers for the Global Cancer Vaccines Market 10
3.6 Opportunity and Unmet Need 11
3.7 Key Takeaway 12
 

4 Cervical Cancer Vaccines Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Marketed Cervical Cancer Vaccine 14
4.3.1 Gardasil 14
4.3.2 Cervarix 15
4.4 Key Takeaway 17
 

5 Prostate Cancer Vaccines 18
5.1 Prostste Cancer Vaccines Market Size 18
5.2 Prostate Cancer Vaccines Market Forecast and CAGR 18
5.3 Drivers and Barriers for the Global Prostate Cancer Vaccines Market 19
5.3.1 Drivers for the Global Prostate Cancer Vaccines Market 19
5.3.2 Barriers for the Global Prostate Cancer Vaccines Market 20
 

6 Cancer Vaccines: Pipeline Assessment 21
6.1 Overview 21
6.2 Future Cancer Vaccines Market Forecast 21
6.3 Strategic Pipeline Assessment 22
6.3.1 Technology Trends Analytic Framework 22
6.4 Cancer Vaccines Pipeline Promising Vaccines Under Clinical Development 24
6.5 Molecule Profile for Promising Cancer Vaccines Under Clinical Development 26
6.5.1 BiovaxID 26
6.5.2 Stimuvax 27
6.5.3 OncoVAX 28
6.5.4 MAGE-A3 ASCI 29
6.5.5 Oncovex (GM-CSF) 30
6.6 Cancer Vaccines Pipeline by Type of Vaccine 32
6.7 Global Cancer Vaccines Pipeline Pipeline by Clinical Phases of Development 33
6.7.1 Cancer Vaccines Regulatory Filing and Phase III Clinical Pipeline 33
6.7.2 Cancer Vaccines Phase II Clinical Pipeline 36
6.7.3 Cancer Vaccines Phase I Clinical Pipeline, 2010 54
6.7.4 Cancer Vaccines Preclinical Pipeline 68
6.7.5 Cancer Vaccines Discovery Pipeline 69
6.8 Key Takeaway 70
 

7 Cancer Vaccines Market: Implications for Future Market Competition 71
 

8 Global Cancer Vaccines Market: Prominent Market Players 73
8.1 Introduction 73

8.2 Merck & Co 73
8.2.1 Overview 73
8.2.2 Financial Performance 74
8.2.3 Business Description 74
8.2.4 Pipeline Products 74
8.2.5 Cancer Vaccines Product Portfolio 74
8.2.6 V503 74
8.3 Merck KGaA 75
8.3.1 Overview 75
8.3.2 Financial Performance 75
8.3.3 Business Description 75
8.3.4 Pipeline Products 76
8.3.5 Cancer Vaccines Product Portfolio 76
8.3.6 Stimuvax 76
8.4 Dendreon Corporation 77
8.4.1 Overview 77
8.4.2 Financial Performance 77
8.4.3 Business Description 77
8.4.4 Cancer Vaccines Product Portfolio 78
8.5 Vaccinogen Inc 79
8.5.1 Overview 79
8.5.2 Pipeline Products 79
8.5.3 Cancer Vaccines Product Portfolio 80
8.6 GlaxoSmithKline Plc. 80
8.6.1 Overview 80
8.6.2 Oncology Portfolio 81
8.6.3 Cancer Vaccines Product Portfolio 81
 

9 Global Cancer Vaccines Market: Appendix 83
9.1 Market Definitions 83
9.2 Abbreviations 83
9.3 Research Methodology 84
9.3.1 Coverage 84
9.3.2 Secondary Research 84
9.3.3 Forecasting 85
9.3.4 Primary Research 88
9.3.5 Expert Panels Validation 88
9.4 Contact Us 88
9.5 Disclaimer 88
9.6 Sources 89

List of Table

 

Table 1: Cervical Cancer Vaccines, Global, Market Revenue ($bn), 20012009 9

Table 2: Cervical Cancer Vaccines Market, Global, Forecast ($bn), 20092017 9

Table 3: Comparison of Marketed Vaccines for Cervical Cancer, 2010 16

Table 4: Prostate Cancer Vaccines Market, Global, Revenue Forecast ($m), 20102017 19

Table 5: Cancer Vaccines Pipeline Most Promising Vaccines under Clinical Development, 2010 24

Table 6: Cancer Vaccines Regulatory Filling and Phase III Clinical Pipeline, 2010 33

Table 7: Cancer Vaccines Phase II Clinical Pipeline, 2010 36

Table 8: Cancer Vaccines Phase I Clinical Pipeline, 2010 54

Table 9: Cancer Vaccines Preclinical Pipeline, 2010 68

Table 10: Cancer Vaccines Discovery Pipeline2010 69

Table 11: Merck Corporation Oncology Pipeline Products, October 2010 74

Table 12: Merck Corporation Oncology Pipeline Products, October 2010 76

Table 13: Dendreon Corporation Oncology Pipeline Products, October 2010 78

Table 14: Vaccinogen Inc. Oncology Pipeline Products, October 2010 79

Table 15: GlaxoSmithKline Plc. Oncology Pipeline Products, October 2010 81

List of Chart

 

Figure 1: Cervical Cancer Vaccines Market, Global, Revenue ($bn), 20012009 8

Figure 2: Cervical Cancer Vaccines Market, Global, Forecast ($bn), 20092017 9

Figure 3: Opportunity and Unmet Need in the Cancer Vaccines Market, 2010 11

Figure 4: Cervical Cancer Vaccines Market, Global, Strategic Competitor Assessment, 2010 13

Figure 5: Prostate Cancer Vaccines Market, Global, Revenue Forecast ($m), 20102017 18

Figure 6: Cancer Vaccines Market, Global, Forecast Revenue ($bn), 20112017 21

Figure 7: Technology Trends Analytic Framework of the Late Stage Global Cancer Vaccines Pipeline, 2010 22

Figure 8: Technology Trends Analytic Framework of the Late Stage Global Cancer Vaccines Pipeline Description, 2010 23

Figure 9: Cancer Vaccines Market, Global, Clinical Pipeline by Vaccine Type, %, 2010 32

Figure 10: Cancer Vaccines Pipeline by Phase of Clinical Development, October 2010 33

Figure 11: Implications for Future Market Competition in the Cancer Vaccines Market, 2010 71

Figure 12: Global Cancer Vaccines Therapeutics Market Clinical Pipeline by Company, 2010 73

Figure 13: GlobalData Market Forecasting Model 87

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *